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Objectives. We 1) evaluated whether interleukin-6 (IL-6) is
produced in the peripheral circulation in patients with congestive
heart failure (CHF), 2) estimated the factors for increased IL-6,
and 3) clarified the prognostic role of high plasma levels of IL-6 in
patients with CHF.
Background. Although plasma levels of IL-6 have been reported
to increase in patients with CHF, and production of IL-6 in
endothelial cells and vascular smooth muscle cells has been
postulated from in vitro studies, the origin of the increase of IL-6
in CHF remains unknown. Moreover, the prognostic value of a
high plasma level of IL-6, independent of classic neurohumoral
factors, remains to be elucidated.
Methods. A comparison was made of the plasma levels of IL-6
between the femoral artery and the femoral vein in 13 normal
subjects and in 80 patients with CHF. In another study, we
measured plasma IL-6 in 100 patients with CHF and follow-up
data.
Results. Plasma IL-6 levels increased significantly from the
femoral artery to the femoral vein in normal subjects and in
patients with CHF. Arteriovenous IL-6 spillover in the leg in-
creased with the severity of CHF. Among the hemodynamic
variables and the various neurohumoral factors, the plasma
norepinephrine (NE) level showed an independent and significant
positive relation with the plasma IL-6 level in patients with CHF.
Moreover, treatment with beta-adrenergic blocking agents showed
an independent and significant negative relation with plasma IL-6
levels. In 100 patients, plasma IL-6 (p < 0.0001), NE (p 5 0.0004)
and left ventricular ejection fraction (0.015) were significant
independent prognostic predictors by Cox proportional hazards
analysis.
Conclusions. Our findings indicate that the IL-6 spillover in the
peripheral circulation increases with the severity of CHF and that
the increase in plasma IL-6 is mainly associated with the activa-
tion of the sympathetic nervous system. High plasma levels of IL-6
can provide prognostic information in patients with CHF, inde-
pendent of left ventricular ejection fraction and plasma NE,
suggesting an important role for IL-6 in the pathophysiology of
CHF.
(J Am Coll Cardiol 1998;31:391–8)
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Hemodynamic abnormality as well as overexpression of neu-
rohormonal factors has been considered to play an important
role in the progression of congestive heart failure (CHF).
Increased levels of various vasoconstrictor neurohumoral fac-
tors have been found in patients with chronic CHF (1–6), and
high plasma levels of norepinephrine (NE), renin and
endothelin-1 (ET-1) have been reported to be significant
prognostic predictors (4,7,8), suggesting an important role for
vasoconstrictors in the pathogenesis of CHF. High levels of
vasodilator neurohumoral factors have also been found in
patients with CHF, and a high plasma level of cardiac natri-
uretic peptides has been reported to be a significant prognostic
predictor (7,9–11). In addition, recent studies have indicated
the potential role of the immune system in the pathophysiology
of CHF (12–14). However, whether cytokines play a significant
role in the pathophysiology or prognosis of CHF, or both,
independent of classic neurohumoral factors, remains to be
elucidated.
Interleukin-6 (IL-6) is a multifunctional proinflammatory
and vasodepressor cytokine that mediates both immune and
inflammatory responses (15). The recent interest in studying
IL-6 in CHF has been prompted by the observation that IL-6,
like tumor necrosis factor (TNF)-alpha, can produce not only
myocardial dysfunction (16) but also abnormal endothelium-
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dependent vasodilation (17) and muscle wasting (18,19). Al-
though elevated levels of IL-6 have been recently identified in
patients with CHF (20,21), the origin of the increase remains
unknown. IL-6 is produced not only in leukocytes (15,22,23)
but also in endothelial cells (24) and vascular smooth muscle
cells (25) in vitro, and its secretion from the endothelium was
increased by ET-1 (26), a potent vasoconstrictor (27), suggest-
ing that the local production of IL-6 regulates vascular resis-
tance or permeability, or both, in patients with CHF. We
hypothesized that local IL-6 production from the peripheral
vascular beds increases with the severity of CHF and is related
to muscle wasting in patients with severe CHF. In addition,
IL-6 and the IL-6 receptor complex, including gp-130, play an
important role in ventricular hypertrophy (28) and left ventric-
ular remodeling, and the high concentration of IL-6 may exert
endocrine effects such as a decrease of left ventricular contrac-
tility through nitric oxide production (16), indicating that
patients with CHF with high plasma levels of IL-6 may have a
poor prognosis. Therefore, the present study was performed 1)
to determine the difference in arterial and venous IL-6 levels;
2) to evaluate the factors for increased IL-6; and 3) to clarify
the prognostic role of high plasma levels of IL-6 in patients
with CHF.
Methods
Study 1. Patients. We studied 80 patients with CHF who
were without renal failure, infection, malignancy or collagen
disease and who underwent cardiac catheterization for clinical
indications. We also selected 13 age-matched normal subjects
who were admitted complaining of chest pain, which proved to
be normal by coronary angiography. Written informed consent
was obtained from all patients before participation in the
study, and the protocol was approved by the Human Investi-
gations Committee of our institution. The subjects included 60
men and 20 women (age range 27 to 79 years, mean 59).
Forty-eight patients had a myocardial infarction more than 3
months before the study, and 32 had dilated cardiomyopathy.
Fifty-six patients were classified according to the standards of
the New York Heart Association as functional class II, 14
patients as class III and 10 patients as class IV. At the
beginning of the study, 63 patients were treated with diuretic
agents, 41 with angiotensin-converting enzyme inhibitors, 40
with digitalis, 60 with vasodilators, 15 with beta-blockers and 5
with docarpamine, an orally active dopamine prodrug (29). All
drug treatments were discontinued at least 12 h before the
study.
Protocol. All patients were premedicated with an oral dose
of diazepam (5 mg) and left to rest in bed in the supine
position for at least 20 min. Right-sided cardiac catheterization
was performed using a 7F Swan-Ganz catheter. The heart rate
was monitored by electrocardiography. Blood samples for
measuring plasma IL-6 and TNF-alpha were collected simul-
taneously from the right femoral artery and vein. Blood
samples for measuring the plasma levels of NE, epinephrine,
angiotensin II and ET-1 were also drawn from the right
femoral artery. A Swan-Ganz catheter was inserted through
the right femoral vein into the main pulmonary artery, where
the pressure was measured. All blood sampling was done
within 5 min before the administration of contrast medium and
heparin. Cardiac output was determined by the thermodilution
method immediately after blood collection. Left ventriculog-
raphy was performed with a contrast medium or radioisotope
before or within 1 week of the hemodynamic measurements
and blood sampling.
Measurement of IL-6 and TNF-alpha. Blood for the mea-
surement of plasma levels of IL-6 and TNF-alpha was trans-
ferred to a chilled tube containing EDTA (1 mg/ml) and
aprotinin (500 kallikrein inactivator U/ml), and then centri-
fuged at 3,000 rpm for 15 min at 4°C. The plasma thus obtained
was stored at 230°C until it was assayed. Both IL-6 and
TNF-alpha measurements were performed using a commer-
cially available immunoassay (Quantikine HS, R&D Systems).
The intraassay coefficients of variation for IL-6 and TNF-alpha
are 3.6% and 6.1%, respectively; the intraassay coefficients of
variation for IL-6 and TNF-alpha are 3.8% and 7.8%, respec-
tively. The minimal detectable values of TNF-alpha and IL-6
were 0.12 and 0.094 pg/ml, respectively. The assay system for
IL-6 has no cross reactivity for other cytokines, including
TNF-alpha, and the assay system for TNF-alpha has no cross
reactivity for other cytokines, including IL-6.
Measurement of immunoreactive ET-1 and other vasocon-
strictor factors. Blood for the measurement of plasma ET-1
levels was transferred to a chilled tube containing EDTA (1
mg/ml) and aprotinin (500 kallikrein inactivator U/ml) and
then centrifuged at 3,000 rpm for 15 min at 4°C. The plasma
thus obtained was stored at 230°C until it was assayed.
Extraction of ET-1 was performed by mixing 2 ml of plasma
with 0.4 ml of 60% methanol containing 0.25 mg/ml of
Preparative C18 (Waters Chromatography Division). The re-
covery rate was calculated to be 72 6 3.9% (n 5 5) by
iodine-125 ET-1 with this method. The plasma ET-1 levels was
determined by using an antibody directed against synthetic
ET-1 (Peninsula Laboratories, Inc.) and iodine-125 ET-1
(Amersham Japan, Tokyo, Japan), as previously reported (6).
This antibody showed 100% cross reactivity with ET-1, 7%
with ET-2, 7% with ET-3 and 17% with human big ET-1.
However, it did not cross react with angiotensin I or II,
vasopressin or human cardiac natriuretic peptides. The mini-
mal detectable level of ET-1 was 0.5 pg/tube; the interassay
Abbreviations and Acronyms
AMP 5 adenosine monophosphate
ANP 5 atrial natriuretic peptide
CHF 5 congestive heart failure
ET-1 5 endothelin-1
IL-6 5 interleukin-6
NE 5 norepinephrine
TNF 5 tumor necrosis factor
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coefficient of variation was 13% (n 5 10); and the intraassay
coefficient of variation was 11% (n 5 9).
Blood for measurement of the plasma levels of NE, epi-
nephrine and angiotensin II was transferred to a chilled tube
containing EDTA (1 mg/ml) and centrifuged at 3,000 rpm for
15 min at 4°C, and the plasma thus obtained was stored at
230°C until assay. Plasma NE and epinephrine concentrations
were measured by high performance liquid chromatography.
Plasma angiotensin II levels were measured by a radioimmu-
noassay using a specific antibody directed against synthetic
angiotensin II (Special Research Laboratory, Tokyo, Japan),
as previously reported (6).
Calculations. The mean blood pressure and systemic vas-
cular resistance were calculated from standard formulas. The
index of the amount of IL-6 spillover in the peripheral
circulation was determined with the following formula (30):
(IL-6 level at site of femoral vein 2 IL-6 level in femoral
artery) 3 Cardiac output 3 (1 2 Hematocrit/100) (ng/min).
Study 2. Patients. The group consisted of 100 patients with
chronic CHF (75 men and 25 women; age range 17 to 82 years,
mean 59) admitted to the hospital at our institution. The cause
of heart failure was dilated cardiomyopathy in 41 patients,
ischemic heart disease (old myocardial infarction .3 months
after the attack) in 53 patients and hypertensive heart disease
in 6 patients. The mean left ventricular ejection fraction was
39% by left ventriculography with a radionuclide or contrast
medium. Patients who had an infection, chronic inflammatory
disease, malignancy or renal failure were excluded. Forty-five
patients were in functional class II heart failure, 35 in class III
and 20 in class IV. All patients were clinically stable with
constant doses of diuretic agents; 75 patients were treated with
digoxin, 68 with angiotensin-converting enzyme inhibitors, 50
with vasodilators and 15 with beta-blockers. All drugs were
administered for at least 4 weeks (most drugs .3 months).
Protocol. Blood samples for the measurement of plasma
atrial natriuretic peptide (ANP), NE and IL-6 were collected
from the peripheral vein after at least 30 min of bed rest with
the patients in the supine position. Left ventriculography was
performed with a contrast medium or radioisotope before or
within 1 week of the blood sampling. Thirty-one patients had a
cardiac death during the follow-up period (after 0.5 to 24
months). All surviving patients were followed up for .3
months (mean 28 months, range 3 to 54).
Measurements of NE, IL-6 and ANP. Measurements of NE
and IL-6 were obtained as in study 1. Samples for the assay of
the plasma ANP concentrations were transferred to chilled
disposable tubes containing aprotinin (500 kallikrein inactiva-
tor U/ml). The blood samples were immediately placed on ice
and centrifuged at 4°C. Plasma ANP concentrations were
measured with a specific immunoradiometric assay for alpha-
human ANP using a commercial kit (Shionoria, Japan), as
previously reported (11). Briefly, this assay used two monoclo-
nal antibodies against alpha-human ANP, one recognizing a
carboxyterminal sequence and the other the ring structure of
ANP, and measured alpha-human ANP by sandwiching it
between the two antibodies without plasma extraction. The
minimal detectable quantity of alpha-human ANP was 5 pg/ml.
The intraassay and interassay coefficients of variation were
5.1% and 5.8%, respectively. This assay system did not cross
react with angiotensin I or II, vasopressin or human brain
natriuretic peptide.
Statistical analysis. All results were expressed as the mean
value 6 SEM. Comparison of the plasma levels of IL-6 and
TNF-alpha at the femoral artery and femoral vein was done
using the paired Student t test. Comparisons between multiple
groups were determined by one-way analysis of variance with
the Scheffe´ F test. Univariate and stepwise multivariate linear
regression analyses were used to detect independent predictors
of plasma IL-6 and IL-6 spillover in the peripheral circulation
among 22 variables. Linear regression analysis was used to
determine the relations between continuous variables. Kaplan-
Meier analysis was performed on the cumulative rates of
survival in patients with CHF stratified into two groups on the
basis of median plasma levels of IL-6, and the differences
between survival curves were analyzed by the log-rank test. To
determine whether the plasma IL-6 concentration seen in our
patients with CHF was an independent prognostic factor or
only reflected the importance of other factors, eight variables,
as listed in Table 1, were entered into a Cox proportional
hazards analysis (univariate and stepwise multivariate analy-
ses). A p value ,0.05 was considered to indicate statistical
significance.
Table 1. Hemodynamic Data
HR
(beats/min)
LVEF
(%)
RAP
(mm Hg)
MPAP
(mm Hg)
PCWP
(mm Hg)
CI
(liters/min per m2)
MBP
(mm Hg)
SVR
(dyneszszcm25)
Normal
(n 5 13)
71.9 6 3.5 64 6 3.2 1.8 6 0.5 11.5 6 0.9 5.2 6 0.8 3.0 6 0.1 86 6 2.3 1,544 6 103
Mild CHF
(n 5 56)
70.7 6 1.7 39 6 1.3* 2.8 6 0.4 18.7 6 0.9† 10.9 6 0.6† 2.8 6 0.1 88 6 1.9 1,605 6 53
Severe CHF
(n 5 24)
87.6 6 3.0‡ 32 6 2.0‡ 6.6 6 1.0§ 28.7 6 2.5§ 18.0 6 1.8§ 2.6 6 0.1 88 6 2.8 1,665 6 78
*p , 0.001, †p , 0.05, versus normal subjects by analysis of variance with Scheffe´ F test. ‡p , 0.05, §p , 0.01 versus normal subjects and patients with mild
congestive heart failure (CHF) (functional class II) by analysis of variance with Scheffe´ F test. Data presented are mean value 6 SEM. CI 5 cardiac index; HR 5 heart
rate; LVEF 5 left ventricular ejection fraction; MBP 5 mean arterial blood pressure; MPAP 5 mean pulmonary artery pressure; PCWP 5 pulmonary capillary wedge
pressure; RAP 5 right atrial pressure; SVR 5 systemic vascular resistance; Severe CHF 5 patients with severe congestive heart failure (functional class III or IV).
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Results
Hemodynamic data (Table 1). The left ventricular ejection
fraction was significantly lower in patients with severe CHF
than in patients with mild CHF. In contrast, the mean pulmo-
nary artery pressure and pulmonary capillary wedge pressure
increased with the severity of CHF. Systemic vascular resis-
tance was slightly higher in patients with severe CHF than in
patients with mild CHF.
Neurohumoral and cytokine data (Table 2). Plasma levels
of NE, epinephrine and ET-1 were significantly higher in
patients with severe CHF than in patients with mild CHF.
Plasma levels of TNF-alpha were significantly higher both in
the femoral artery and in the femoral vein in patients with
severe CHF than in patients with mild CHF. Plasma levels of
IL-6 were also significantly higher both in the femoral artery
and in the femoral vein in patients with severe CHF than in
patients with mild CHF.
Plasma IL-6 concentrations and IL-6 spillover in the
peripheral circulation. Figure 1 shows the plasma levels of
TNF-alpha and IL-6 at the femoral artery and femoral vein in
age-matched normal subjects and patients with CHF. There
was no difference in plasma TNF-alpha levels between the
femoral artery and the femoral vein both in normal subjects
and in patients with CHF. In contrast, plasma IL-6 concentra-
tions increased significantly from the femoral artery to the
femoral vein in normal subjects and in patients with CHF. IL-6
spillover in the leg was markedly increased in patients with
severe CHF compared with normal subjects and patients with
mild CHF (Fig. 2). Both plasma IL-6 levels and IL-6 spillover
in the leg were significantly higher in female patients than in
male patients (Fig. 3).
Relation between plasma IL-6 concentrations and 22 vari-
ables, including hemodynamic data, clinical variables and
neurohumoral factors. On univariate analysis, there were
significant correlations between the plasma IL-6 concentration
and hemodynamic data such as heart rate, right atrial pressure,
mean pulmonary artery pressure, pulmonary capillary wedge
pressure and left ventricular ejection fraction. There were also
significant positive correlations between the plasma IL-6 level
and other biochemical factors such as NE (Fig. 4), epineph-
rine, ET-1, TNF-alpha and angiotensin-II levels. In addition,
plasma IL-6 levels were significantly higher in female patients
and in patients with severe symptoms or those treated with
docarpamine (Table 3). On multivariate analysis, plasma levels
of NE and epinephrine showed independent and significant
positive relations with the plasma IL-6 level, and treatment
with beta-blockers showed independent and significant nega-
tive relations with plasma IL-6 levels among 22 variables
(Table 3). Moreover, female gender was also an independent
significant predictor of high plasma levels of IL-6 in patients
with CHF (Table 3).
Relation between plasma IL-6 spillover in the peripheral
circulation and 22 variables, including hemodynamic data,
clinical variables and neurohumoral factors. On univariate
analysis, there were significant correlations between the
Figure 1. Plasma levels of IL-6 and TNF-alpha in the femoral artery
(FA) and femoral vein (FV) in normal subjects and in patients with
CHF. *p , 0.01 and **p , 0.001 compared with the value of IL-6 in
the femoral artery. #p , 0.01 compared with mild CHF (analysis of
variance with the Scheffe´ F test).
Table 2. Neurohumoral and Cytokine Data
NE
(pg/ml)
Epi
(pg/ml)
Ang II
(pg/ml)
ET-1
(pg/ml)
TNF-Alpha IL-6
FA
(pg/ml)
FV
(pg/ml)
FA
(pg/ml)
FV
(pg/ml)
Normal
(n 5 13)
209 6 27 32 6 5 10 6 3 2.1 6 0.2 2.8 6 0.4 2.7 6 0.4 1.0 6 0.2 1.2 6 0.2
Mild CHF
(n 5 56)
329 6 38 28 6 3.3 18 6 2.4 2.3 6 0.1 4.2 6 0.3 4.3 6 0.3 2.6 6 0.2 2.9 6 0.3
Severe CHF
(n 5 24)
931 6 180* 78 6 17* 27 6 7 3.9 6 0.5* 5.8 6 0.8† 5.4 6 0.7† 18.3 6 7.8‡ 20.9 6 8.5‡
*p , 0.01, †p , 0.05 versus normal subjects and patients with mild congestive heart failure (CHF) (functional class II) by analysis of variance with Scheffe´ F test.
‡p , 0.01 versus patients with mild congestive heart failure by analysis of variance with Scheffe´ F test. Data presented are mean value 6 SEM. Ang 5 angiotensin II;
Epi 5 epinephrine; ET-1 5 endothelin-1; FA 5 femoral artery; FV 5 femoral vein; IL-6 5 interleukin-6; NE 5 norepinephrine; TNF-Alpha 5 tumor necrosis
factor-alpha.
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plasma IL-6 spillover in the peripheral circulation and hemo-
dynamic data such as heart rate, right atrial pressure, mean
pulmonary artery pressure, pulmonary capillary wedge pres-
sure and left ventricular ejection fraction, as well as other
biochemical factors such as NE, epinephrine, ET-1, TNF-alpha
and angiotensin-II levels. In addition, plasma IL-6 spillover in
the peripheral circulation was significantly higher in female
patients and in patients with severe symptoms or those treated
with docarpamine (Table 4). On multivariate analysis, only
high plasma NE levels and treatment with docarpamine
showed independent and significant positive relations with the
plasma IL-6 spillover in the peripheral circulation (Table 4).
Relation between plasma IL-6 spillover in the peripheral
circulation and body mass index. Although there was no
correlation between plasma IL-6 levels in the femoral artery or
vein and body mass index, there was a significant negative
correlation between plasma IL-6 spillover in the peripheral
circulation and body mass index in patients with CHF (r 5
20.24, p 5 0.034).
High plasma levels of IL-6 as a predictor of mortality in
patients with CHF. Eight variables, including functional class,
ejection fraction, neurohumoral variables and plasma IL-6
levels, were analyzed using univariate and stepwise multivari-
ate Cox proportional hazards regression analyses in study 2
groups (Table 5). On univariate analyses, high plasma levels of
NE, ANP and IL-6, functional class, ejection fraction and age
were significant predictors of mortality. According to stepwise
multivariate analyses, only high plasma levels of IL-6 (p ,
0.0001) and NE (p 5 0.0004) and a low left ventricular ejection
fraction were significant independent predictors (Table 5). An
elevated level of plasma IL-6 was a prognostic predictor by
Kaplan-Meier analysis (Fig. 5).
Figure 2. Interleukin-6 spillover in the peripheral circulation in nor-
mal subjects and in patients with CHF. *p , 0.05 compared with the
value for normal subjects and those with mild CHF (analysis of
variance with the Scheffe´ F test).
Figure 3. Gender difference of plasma IL-6 level and IL-6 spillover in
the peripheral circulation in patients with CHF. *p , 0.001 compared
with the value for male patients.
Figure 4. Relation between the plasma levels of NE and IL-6 concen-
trations in patients with CHF.
Table 3. Univariate and Multivariate Linear Model of Plasma
Interleukin-6 in Femoral Vein of Patients With Congestive
Heart Failure
Variable
Univariate
Corr Coeff
p
Value
Multivariate
Beta-Coeff
(SE)
p
Value
Age 0.185 0.095 NS
Gender (M 5 0;
F 5 1)
0.351 0.0012 4.06 (1.77) 0.024
Functional class 0.388 0.0003 NS
Diuretic drugs* 20.04 0.732 NS
Digitalis* 0.14 0.208 NS
ACE inhibitors* 20.125 0.263 NS
Vasodilators* 20.20 0.071 NS
Beta-blockers* 20.08 0.498 26.16 (2.54) 0.017
Docarpamine* 0.479 , 0.0001 NS
HR 0.343 0.0016 NS
MBP 20.09 0.411 NS
CI 0.122 0.275 NS
RAP 0.325 0.0029 NS
MPAP 0.231 0.036 NS
PCWP 0.295 , 0.0001 NS
LVEF 20.323 0.0031 NS
NE 0.839 , 0.0001 0.015 (0.001) , 0.0001
Epi 0.676 , 0.0001 0.103 (0.011) , 0.0001
ET-1 0.576 , 0.0001 NS
TNF-alpha 0.381 0.0004 NS
Ang II 0.376 0.0005 NS
WBC 0.151 0.177 NS
*Treatment 5 1; no treatment 5 0. ACE 5 angiotensin-converting enzyme;
Coeff 5 coefficient; Corr 5 correlation; F 5 female; M 5 male; WBC 5 white
blood cells; other abbreviations as in Tables 1 and 2.
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Discussion
We detected IL-6 spillover in the peripheral circulation of
normal subjects and demonstrated that it increased in relation
to the severity of CHF, suggesting that part of the source of the
increased plasma IL-6 was the peripheral circulation in pa-
tients with CHF. In contrast, there was no difference in plasma
TNF-alpha levels between the femoral artery and vein in
patients with CHF. In the present study, both plasma IL-6 and
TNF-alpha concentrations were increased in patients with
severe CHF, consistent with other studies (20,21). The origin
of the increase is thought to be mainly leukocytes, including
macrophages and lymphocytes (22,23). Because IL-6 was pro-
duced not only by leukocytes but also by endothelial cells and
vascular smooth muscle cells in vitro (24,25), our findings
suggest that IL-6 is produced by the vascular tissue in patients
with severe CHF. We cannot rule out that the arteriovenous
difference in IL-6 is derived from the leukocytes, which adhere
to endothelial cells, but there was no arteriovenous difference
in TNF-alpha, suggesting that the main source of IL-6 spillover
in the peripheral circulation is the vascular endothelial cells or
smooth muscle cells. Although the pathophysiologic role of
IL-6 production in the peripheral circulation remains un-
known, local IL-6 production may contribute to abnormalities
of endothelium-dependent vasodilation, vascular resistance,
increased vascular permeability (31) or muscle wasting (18,19)
in patients with severe CHF. Indeed, there was a significant
negative correlation between IL-6 spillover in the peripheral
circulation and body mass index. Muscles of IL-6–producing
transgenic mice suffer from atrophy and IL-6 receptor antibody
inhibits muscle atrophy in this model (19); thus, the increase in
IL-6 production in the peripheral circulation may contribute to
muscle wasting in patients with CHF.
Why are the plasma IL-6 levels increased in patients with
CHF? Because both TNF-alpha and ET-1 are increased in
CHF (5,6,12,21) and stimulate IL-6 production in the endo-
thelium in vitro (26,32), we hypothesized that IL-6 spillover is
regulated by the local plasma levels of TNF-alpha and ET-1.
Although there was a significant positive correlation between
the plasma levels of IL-6 and TNF-alpha and ET-1 on univar-
iate analysis, no significant relation was obtained between the
plasma level of IL-6 and the plasma levels of TNF-alpha and
ET-1 when the plasma NE level was included by multivariate
analysis. Interleukin-6 has been reported to be produced in
various cells, including lymphocytes, monocytes, granulocytes,
mast cells and endothelial cells. Although the mechanism of
the increase of IL-6 production has not been fully elucidated,
IL-6 secretion is increased through an elevation of intracellular
cyclic adenosine monophosphate (AMP) levels (33,34), sug-
gesting that the main mechanism for regulation of the increase
of IL-6 spillover in the peripheral vascular circulation is activity
of the sympathetic nervous system involving probably an
Figure 5. Kaplan-Meier analysis of cumulative rates of survival in
patients with CHF stratified into two groups on the basis of median
plasma concentration (4.6 pg/ml) of IL-6.
Table 4. Univariate and Multivariate Linear Model of Interleukin-6
Spillover in Peripheral Circulation of Patients With Congestive
Heart Failure
Variable
Univariate
Corr Coeff
p
Value
Multivariate
Beta Coeff
(SE)
p
Value
Age 0.121 0.28 NS
Gender (m 5 0;
F 5 1)
0.329 0.0025 NS
Functional class 0.320 0.0034 NS
Diuretic drugs* 20.03 0.817 NS
Digitalis* 0.08 0.44 NS
ACE inhibitors* 20.09 0.408 NS
Vasodilators* 20.163 0.143 NS
Beta-blockers* 20.06 0.603 NS
Docarpamine* 0.677 , 0.0001 14.38 (2.8) , 0.0001
HR 0.256 0.02 NS
MBP 20.121 0.075 NS
CI 0.165 0.138 NS
RAP 0.261 0.017 NS
MPAP 0.252 0.022 NS
PCWP 0.262 0.017 NS
LVEF 20.242 0.0288 NS
NE 0.875 , 0.0001 0.0013 (0.001) , 0.0001
Epi 0.348 , 0.0001 NS
ET-1 0.557 , 0.0001 NS
TNF-alpha 0.510 , 0.0001 NS
Ang II 0.338 0.0019 NS
WBC 0.124 0.267 NS
*Treatment 5 1; no treatment 5 0. Abbreviations as in Tables 1 to 3.
Table 5. Univariate and Multivariate Predictors of Mortality in 100
Patients With Chronic Heart Failure
Variable
Univariate
Chi-Square
p
Value
Multivariate
Chi-Square
p
Value
NE 32.9 , 0.0001 12.55 0.0004
ANP 27.5 , 0.0001 2.78 0.095
IL-6 18.8 , 0.0001 19.01 , 0.0001
Functional class 8.93 0.0028 1.55 0.213
LVEF 6.88 0.0087 5.92 0.015
Age 5.03 0.025 0.151 0.697
Gender 1.19 0.275 2.63 0.105
Etiology (DCM,
non-DCM)
0.012 0.913 0.90 0.764
ANP 5 atrial natriuretic peptide; DCM 5 dilated cardiomyopathy; other
abbreviations as in Tables 1 and 2.
396 TSUTAMOTO ET AL. JACC Vol. 31, No. 2
IL-6 AND PROGNOSIS OF CONGESTIVE HEART FAILURE February 1998:391–8
increase in intracellular cyclic AMP. Docarpamine, an orally
active dopamine prodrug, is also known to increase intracellu-
lar cyclic AMP through the dopamine receptor, and the finding
that treatment with docarpamine is a significant predictor of
IL-6 spillover independent of plasma NE level supports our
hypothesis. Because IL-6 inhibits vascular constriction by
phenylephrine in vitro (35), an increase in its IL-6 production
in the peripheral vascular tissue may counteract the excessive
vasoconstriction through the alpha receptor by stimulation of
the sympathetic nervous system in patients with CHF. The
local increase of IL-6 production in the vascular smooth
muscle cells also increases inducible nitric oxide synthase and
may cause a compensatory vasodilation against various acti-
vated vasoconstrictors such as ET-1, angiotensin II and NE in
patients with CHF.
The increase in the plasma levels of IL-6, which is derived
from various cells including leukocytes (lymphocytes, macro-
phages and granulocytes), is also regulated by plasma levels of
catecholamines such as NE and epinephrine. In the present
study, interestingly, treatment with beta-blockers showed a
negative relation to plasma IL-6 levels in patients with CHF.
These findings indicate that the increase in IL-6 production in
not only vascular tissue but also in other cells such as lympho-
cytes and macrophages is mainly associated with activation of
the sympathetic nervous system in patients with CHF. More-
over, female gender also shows an independent significant
relation to high plasma levels of IL-6 in patients with CHF.
Although various neurohumoral factors including cytokine
concentrations have been reported to increase in CHF, to our
knowledge, there has been no report with regard to a gender
difference independent of severity of CHF or hemodynamic
abnormalities. In the present study, plasma IL-6 levels were
significantly higher in female patients (most were postmeno-
pause). Because it is well known that estrogen loss causes an
increase in IL-6 activity and contributes to the increased bone
resorption in postmenopausal osteoporosis (36), the decrease
of estrogen may increase plasma IL-6 levels in postmenopausal
women with CHF. Indeed, recently, plasma levels of IL-6 were
reported to correlate with postmenopausal status in normal
subjects (37).
Plasma IL-6 levels as an independent prognostic predictor
in patients with CHF. Although concentrations of various
cytokines have been reported to increase in patients with CHF,
it is not clear whether these activations are associated with the
progression of CHF independent of activated classic neurohu-
moral factors or low left ventricular ejection fraction. In the
present study, eight variables, including functional class, ejec-
tion fraction, neurohumoral variables and plasma IL-6 levels,
were analyzed using univariate and stepwise multivariate Cox
proportional hazards regression analyses. As previously re-
ported, high plasma levels of NE and ANP and low left
ventricular ejection fraction were prognostic factors in CHF by
univariate analysis. According to stepwise multivariate analy-
ses, a high plasma level of IL-6 was a significant independent
predictor, suggesting an important role for IL-6 in the patho-
physiology of CHF. The prognostic role of IL-6 is not reflected
by the etiology of CHF (dilated cardiomyopathy or nondilated
cardiomyopathy), also suggesting that a high plasma level of
IL-6 is a significant prognostic predictor independent of etiol-
ogy in patients with chronic CHF. A recent report that IL-6
production is detected in cardiac myocytes and increased by
catecholamine (38) suggests that the increase in plasma IL-6
is partly of ventricular origin, and IL-6 modifies the ven-
tricular function through increase of nitric oxide synthase (16).
Indeed, in the present study, there was a negative correlation
between the plasma IL-6 level and left ventricular ejection
fraction by univariate analysis, but the relation was no longer
significant when the plasma catecholamine level was included
by multivariate analysis, indicating that ventricular IL-6 is a
more important regulator of ventricular dysfunction than
plasma IL-6, because IL-6 acts in an autocrine and a paracrine
manner.
Study limitations. In the present study, blood samples
were collected from the femoral artery and vein to confirm the
spillover or extraction of IL-6 in the peripheral circulation. We
previously used the same methods to evaluate the extraction of
ANP and the production of cyclic guanosine monophosphate
in the peripheral circulation (30). However, the calculated
values for IL-6 spillover may be underestimated because IL-6
acts in an autocrine and paracrine manner. The pathophysio-
logic role of the production of IL-6 in the peripheral circula-
tion of patients with CHF remains unknown and we did not
evaluate endothelium-dependent vasodilation in the present
study; therefore, further studies using IL-6 receptor antago-
nists are need to clarify our hypothesis.
Conclusions. A partial source of circulating IL-6 is the
peripheral vascular bed in normal subjects and in patients with
CHF. Although the physiologic and pathophysiologic role of
IL-6 spillover in the legs remains unclear, IL-6 spillover in the
peripheral circulation increases with the severity of CHF and is
mainly associated with the activation of the sympathetic ner-
vous system. A high plasma level of IL-6 is a prognostic
predictor in patients with CHF independent of left ventricular
ejection fraction and plasma NE, suggesting an important role
for IL-6 in the pathophysiology of CHF.
We thank Ikuko Sakaguchi for excellent technical assistance.
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